It's too early to claim the fate or fortune of IBXOA, but some...

It's too early to claim the fate or fortune of IBXOA, but some of the claims flying around here
are hard to substantiate. We have been advised that further patient enrolments have occurred
every quarter since the original five patients in March 2022 and the trial data obtained to date
has been positive, therefore, there is nothing to suggest any form of failure with the current trial
with what has been announced by management.

Clearly as evidenced by reading these threads there is a wide spectrum of understanding by
holders as to the progress made to date and if in fact the trial will finish by 2022. My opinion
may be just as wrong as many others but I strongly believe that with all the material ann
received to date we have no real basis for projecting failure either with the tech or the patient
cohort being achieved. A formal announcement declaring same will be the only thing that can
now reduce or totally eliminate the market skepticism and I expect that to occur before year's end.